Mycoplasma Testing Market by Product & Service (Assay, Kits, & Reagents; Instruments; and Services), Technology (Polymerase Chain Reaction, ELISA, Staining, and Other Technologies), Application (Cell Line Testing, Virus Testing, and End-of-Production Cell Testing), and End User (Pharmaceutical & Biotechnology Companies, Cell Banks & Laboratories, Contract Research Organization, and Academic Research Organization): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026848 | Pages: 100 | Industry: Biotechnology | Date: Oct 2022 | Type: Global

The market crossed US$ 1.56 billion mark in 2022 and is expected to hit US$ 3.46 billion by 2030, recording a CAGR of 10.42% during the forecast period.      

Increase in cell culture contamination due to mishandling of the cell culture fueling the growth of mycoplasma testing market

Contamination of cell culture is one of the most common problems that is encountered in cell culture laboratories. Contamination of cell culture can be divided into two main categories, viz, chemical contaminants and biological contaminants. Mycoplasma is included under biological contaminants. These mycoplasmas may persist in culture without causing cell death, but they can alter the metabolism and behavior of the host cells. Approximately 190 species of mycoplasma are known out of which eight mycoplasma species are responsible for about 90% of the mycoplasma contamination. Pure cultural practices, aerosols, cross contaminations due to faulty laminar air flow, and dust are some of the major reasons due to which there is increase in mycoplasma contamination. This factor is responsible for the growth of mycoplasma testing market.

Within the report, the market is segmented into product & services, technology, application, end user, and geography. On the basis of product & service, the market is segmented into assay, kits, & reagents; instruments; and services. By assay, kits & reagents, the market is further divided into PCR, ELISA, elimination kits, stains, and others. Based on the technology, the market is segmented into PCR, ELISA, staining and other technologies. On the basis of application, the market is categorized into cell line testing, virus testing, and end of production cells technology. Based on end user, the market is divided pharmaceutical & biotechnology companies, cell banks & laboratories, contract research organization, and academic research institutes. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Increase in research and development activities in developing regions is empowering futuristic market growth.

Mycoplasma is a biological contaminant which is found in laboratories and contaminate the cell culture lines. Mishandling of the cell culture can lead to mycoplasma contamination. Mycoplasma may affect the metabolism of the host cell culture and affect their growth rate; hence it is important to test the cell culture for mycoplasma presence. Leading market players increase their penetration across emerging markets by expanding their distribution networks and augmented manufacturing capabilities. As the US and European markets mature, most players are shifting their focus to emerging markets. Asia Pacific has become a business-friendly and adaptable hub due to relatively less stringent regulations and data requirements. In addition, high investments in life science and health research in emerging countries play a key role in upgrading the latest technologies in developing countries, which, in turn, supports the inclination toward mycoplasma testing. The growing research activities due to rise in investment in these regions is increasing the chances of contamination which creates the opportunity for growth of mycoplasma testing market.

Increase in drug discovery and development in pharmaceutical industry is one of the major factors accelerating the market growth.

The end user for mycoplasma testing are pharmaceutical & biotechnology companies, cell banks & laboratories, contract research organization, and academic research institutes. The pharmaceutical & biotechnology companies are carrying out quality checks of raw materials used in their research work, ensuring the biological safety of the researcher. Also, the increase in research activities due to the increase in prevalence of chronic diseases is fueling the growth of mycoplasma testing market.

Recent strategic developments in mycoplasma testing market

The mycoplasma testing market has undergone several significant developments, and a few of these have been mentioned below:

  • In November 2021, the Life Science Group Sartorius rolled out its Sartolab RF/BT 150-1000 vacuum filtration units. Launched for meeting various applications including mycoplasma removal, the product has been redesigned for offering higher capacity and faster filtration with greater physical stability.
  • In July 2020, bioMérieux launched of BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics. BIOFIRE MYCOPLASMA is an innovative, rapid and very easy-to-use molecular biology test. This is because the DNA extraction, amplification and detection steps are fully automated and may be performed outside of the laboratory by nearly anyone after simple training.
  • In March 2019, Lonza has further strengthened its extensive mycoplasma detection portfolio with the addition of the Lucetta 2 Luminometer, a single-tube system designed to simplify and accelerate mycoplasma detection in cell cultures.

 

The mycoplasma testing market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Thermo Fisher Scientific, Charles River Laboratories, Lonza Group Ltd., Merck Millipore, Roche Diagnostics, American Type Culture Collection, InvivoGen, PromoCell GmbH, Creative Bioarray, and Mycoplasma Experience are among the prominent players operating in the market.

Target audience for the report:

  • Raw material providers
  • Healthcare related service providers
  • End User-related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • End User Industry
  • Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Product & Service:
    • Assays, Kits, & Reagents
      • PCR
      • ELISA
      • Elimination Kits
      • Stains
      • Others
    • Instruments
    • Services
  • Technology
    • PCR
    • ELISA
    • Staining
    • Others
  • Application:
    • Cell Line Testing
    • Virus Testing
    • End of Production Cells Technology
  • End User:
    • Pharmaceutical & Biotechnology Companies
    • Cell Banks & Laboratories
    • Contract Research Organization
    • Academic Research Institutes
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Thermo Fisher Scientific
    • Charles River Laboratories
    • Lonza Group Ltd.
    • Merck Millipore
    • Roche Diagnostics
    • American Type Culture Collection
    • InvivoGen
    • PromoCell GmbH
    • Creative Bioarray
    • Mycoplasma Experience

 

The List of Companies
- Thermo Fisher Scientific
- Charles River Laboratories
- Lonza Group Ltd.
- Merck Millipore
- Roche Diagnostics
- American Type Culture Collection
- InvivoGen
- PromoCell GmbH
- Creative Bioarray
- Mycoplasma Experience

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000